| 2.49 -0.01 (-0.4%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.46 | 1-year : | 4.05 |
| Resists | First : | 2.97 | Second : | 3.46 |
| Pivot price | 2.58  |
|||
| Supports | First : | 2.17 |
Second : | 1.69 |
| MAs | MA(5) : | 2.63 |
MA(20) : | 2.51 |
| MA(100) : | 1.88 |
MA(250) : | 1.59 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 39.9 |
D(3) : | 55.7 |
| RSI | RSI(14): 52.7 |
|||
| 52-week | High : | 3 | Low : | 0.66 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CRBU ] has closed above bottom band by 35.0%. Bollinger Bands are 8.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.61 - 2.62 | 2.62 - 2.63 |
| Low: | 2.41 - 2.43 | 2.43 - 2.45 |
| Close: | 2.46 - 2.49 | 2.49 - 2.52 |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Fri, 24 Oct 2025
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates - MSN
Tue, 23 Sep 2025
Caribou Biosciences stock rating reiterated by H.C. Wainwright - Investing.com
Mon, 25 Aug 2025
CRISPR Leader Caribou Biosciences Featured at Citi 2025 Biopharma Conference - CEO to Share Updates - Stock Titan
Tue, 12 Aug 2025
Caribou Biosciences Reports Increased Losses Amid R&D Efforts - TipRanks
Tue, 12 Aug 2025
CARIBOU BIOSCIENCES Earnings Results: $CRBU Reports Quarterly Earnings - Quiver Quantitative
Tue, 12 Aug 2025
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 93 (M) |
| Held by Insiders | 8.406e+007 (%) |
| Held by Institutions | 9.8 (%) |
| Shares Short | 4,030 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.4626e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 328.3 % |
| Return on Equity (ttm) | -31.8 % |
| Qtrly Rev. Growth | 9.12e+006 % |
| Gross Profit (p.s.) | -8.89 |
| Sales Per Share | -26.62 |
| EBITDA (p.s.) | -4.6278e+007 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -133 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.1 |
| Price to Cash Flow | 3.62 |
| Dividend | 0 |
| Forward Dividend | 4.07e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|